J.C. Eymard

586 total citations
20 papers, 341 citations indexed

About

J.C. Eymard is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J.C. Eymard has authored 20 papers receiving a total of 341 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in J.C. Eymard's work include Renal cell carcinoma treatment (7 papers), Cancer Treatment and Pharmacology (7 papers) and Renal and related cancers (6 papers). J.C. Eymard is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Treatment and Pharmacology (7 papers) and Renal and related cancers (6 papers). J.C. Eymard collaborates with scholars based in France, Greece and Austria. J.C. Eymard's co-authors include Gwénaëlle Gravis, Frédéric Rolland, Stéphane Culine, Christine Chevreau, Stéphane Oudard, Thierry Lesimple, Yacine Merrouche, Frank Priou, Bernard Escudier and Sophie Gourgou and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Journal of Urology.

In The Last Decade

J.C. Eymard

19 papers receiving 333 citations

Peers

Countries citing papers authored by J.C. Eymard

Since Specialization

Citations

This map shows the geographic impact of J.C. Eymard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.C. Eymard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.C. Eymard more than expected).

Fields of papers citing papers by J.C. Eymard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.C. Eymard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.C. Eymard. The network helps show where J.C. Eymard may publish in the future.

Co-authorship network of co-authors of J.C. Eymard

This figure shows the co-authorship network connecting the top 25 collaborators of J.C. Eymard. A scholar is included among the top collaborators of J.C. Eymard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.C. Eymard. J.C. Eymard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation 2023 ·British Journal of Cancer ·Jean‐Sébastien Frenel, Amélie Lusque, Suzette Delaloge, J-M Ferrero, Thomas Bachelot, Isabelle Desmoulins, Christelle Lévy, J.C. Eymard, Anthony Gonçalvès, Anne Patsouris, (unknown), (unknown), Thierry Petit, Luc Cabel, L. Uwer, Marc Debled, M. Chevrot, Audrey Mailliez, William Jacot, Thibault De La Motte Rouge	3
2	Physicians’ satisfaction with health-related quality of life (HRQoL) assessment in daily clinical practice using electronic patient-reported outcome (ePRO) for cancer patients 2019 ·Annals of Oncology ·Guillaume Mouillet, (unknown), Antoine Thiery-Vuillemin, (unknown), Hamadi Almotlak, Luigi Mansi, Elsa Curtit, (unknown), Marine Jary, Tristan Maurina, Guillaume Eberst, Philippe Barthélémy, J.C. Eymard, L. Geoffrois, (unknown), Amélie Anota, Olivier Adotévi, Virginie Westeel, Sophie Paget‐Bailly	0
3	Adjuvant radiation therapy for malignant Abrikossoff’s tumor: a case report about a femoral triangle localisation 2018 ·Radiation Oncology ·(unknown), Christian Garbar, (unknown), Francis Guillemin, (unknown), J.C. Eymard, (unknown)	4
4	UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer 2015 ·Annals of Oncology ·Anthony Gonçalvès, Jean‐Yves Pierga, Jean-Marc Ferrero, Marie‐Ange Mouret‐Reynier, Thomas Bachelot, R. Delva, Michel Fabbro, F. Lerebours, Jean‐Pierre Lotz, Claude Linassier, Nadine Dohollou, J.C. Eymard, Bernard Leduc, Jérôme Lemonnier, Anne‐Laure Martin, Jean‐Marie Boher, Patrice Viens, H. Roché	14
5	Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 2014 ·Annals of Oncology ·(unknown), (unknown), Benoit Beuselinck, J.C. Eymard, Aristotelis Bamias, Éléonore De Guillebon, Camillo Porta, Yann Vano, Claude Linassier, Philip R. Debruyne, Marine Gross‐Goupil, Alain Ravaud, (unknown), Grégoire Marret, Stéphane Oudard	18
6	Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial 2014 ·Annals of Oncology ·Karim Fizazi, Gwénaëlle Gravis, (unknown), L. Geoffrois, Christine Chevreau, Brigitte Laguerre, R. Delva, J.C. Eymard, Frédéric Rolland, Nadine Houédé, A. Laplanche, Domnita-Ileana Burcoveanu, Stéphane Culine	40
7	Prediction of Response of Primary Tumors to Neoadjuvant Sunitinib Using Perfusion (Dce) Computed Tomography (Ct) in Metastatic Renal Cell Carcinoma (Mrcc) Patients (Preinsut Trial) 2014 ·Annals of Oncology ·(unknown), Laure Fournier, Yann Vano, Héléna Pereira, (unknown), Laurent Salomon, S. Taïeb, (unknown), Sophie Abadie‐Lacourtoisie, A Scherrer, Christine Théodore, (unknown), Stéphane Culine, (unknown), J.C. Eymard, (unknown), Gilles Châtellier, Arnaud Méjean, C.A. Cuénod, Stéphane Oudard	1
8	Everolimus for Patients with Metastatic Renal Cell Carcinoma (Mrcc) Refractory to Anti-Vegf Therapy: Updated Results of a Pooled Analysis of Noninterventional Studies 2014 ·Annals of Oncology ·(unknown), (unknown), J.C. Eymard, Manuela Schmidinger, Aristotle Bamias, (unknown), (unknown), (unknown), Carsten Rose, Agnese Cattaneo, Lars Bergmann	1
9	Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? 2011 ·Annals of Oncology ·Renaud Sabatier, J.C. Eymard, Jochen Walz, Jean‐Laurent Deville, H Narbonne, Jean‐Marie Boher, Naji Salem, M. Marcy, Serge Brunelle, Patrice Viens, Franck Bladou, Gwénaëlle Gravis	50
10	7051 POSTER Bicalutamide in Combination With Vandetanib or Placebo in Patients With Castration-refractory Metastatic Prostate Cancer Without Any Clinical Symptom Related to Disease Progression – a Randomized, Double-blind Phase II Trial 2011 ·European Journal of Cancer ·(unknown), Nadine Houédé, Sylvestre Le Moulec, C. Hennequin, J.C. Eymard, Philippe Beuzeboc, Stéphane Oudard, (unknown), (unknown), Karim Fizazi	1
11	Benefit of the Sequential Administration of Docetaxel after Standard FEC Regimen for Node-Positive Breast Cancer: Long-Term Follow-Up Results of the FNCLCC-PACS 01 Trial. 2009 ·Cancer Research ·Bruno Coudert, Mario Campone, M. Spielmann, Michel Symann, (unknown), D. Serin, T. Delozier, Gilles Romieu, Jean Luc Canon, Hubert Orfeuvre, G. Piot, (unknown), P. Chollet, (unknown), B. Audhuy, Corinne Veyret, M. Beauduin, J.C. Eymard, Andrew Martin, Henri Roché	8
12	Post-Operative 5FU-Docetaxel after High-Dose of Pre-Operative Epirubicin-Cyclophosphamide for Treatment of Inflammatory Breast Cancer: Results of the FNCLCC-Pegase 07 Trial. 2009 ·Cancer Research ·Patrice Viens, T Palangié, Jean-Marc Ferrero, P. Chollet, Thomas Bachelot, R. Delva, Michel Fabbro, Maud Janvier, Jean‐Pierre Lotz, Claude Linassier, Nadine Dohollou, J.C. Eymard, Bernard Leduc, Jean Genève, Andrew Martin, Jean‐Marie Boher, Hoffmann-La Roche	2
13	Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial 2007 ·Journal of Clinical Oncology ·C. Sternberg, Daniel P. Petrylak, Fred Witjes, (unknown), J.C. Eymard, S. Falcon, (unknown), David J. Vaughn, William R. Berry, Oliver Sartor	47
14	311 PAIN AND PSA RESPONSES IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER TREATED WITH SATRAPLATIN: RESULTS OF THE SPARC PHASE III TRIAL 2007 ·European Urology Supplements ·J.A. Witjes, Daniel P. Petrylak, Oliver Sartor, Tomasz Demkow, J-M Ferrero, J.C. Eymard, S. Falcon, (unknown), Oliver Krieter, C. Sternberg	1
15	Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report 2004 ·Journal of Clinical Oncology ·J.C. Eymard, Florence Joly, Frank Priou, Alain Zannetti, Alain Ravaud, Pierre Kerbrat, M Mousseau, Bernard Paule, (unknown), (unknown)	7
16	Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pN0) and limited node positive (pN+≤3) breast cancer (BC) patients (pts): First analysis of toxicity 2004 ·Journal of Clinical Oncology ·Étienne Brain, Thomas Bachelot, D. Serin, Y Graïc, J.C. Eymard, Jean-Marc Extra, M. Combe, Catherine Noguès, Jacques Rouëssé	3
17	Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial 2002 ·British Journal of Cancer ·M. Spielmann, M. Tubiana-Hulin, M. Namer, (unknown), Philippe Bougnoux, N. Tubiana-Mathieu, (unknown), J.C. Eymard	17
18	Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers. 2002 ·PubMed ·Bernard Escudier, Jean‐Pierre Droz, Frédéric Rolland, Marie-Josée Terrier-Lacombe, Gwénaëlle Gravis, Philippe Beuzeboc, B. Chauvet, Christine Chevreau, J.C. Eymard, Thierry Lesimple, Yacine Merrouche, Stéphane Oudard, Frank Priou, (unknown), Sophie Gourgou, Stéphane Culine, (unknown)	61
19	Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer Centers 2002 ·The Journal of Urology ·Bernard Escudier, Jean‐Pierre Droz, Frédéric Rolland, Marie-Josée Terrier-Lacombe, Gwénaëlle Gravis, Philippe Beuzeboc, B. Chauvet, Christine Chevreau, J.C. Eymard, Thierry Lesimple, Yacine Merrouche, Stéphane Oudard, Frank Priou, (unknown), Sophie Gourgou, Stéphane Culine	62
20	Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer Centers 2002 ·The Journal of Urology ·Bernard Escudier, Jean‐Pierre Droz, Frédéric Rolland, Marie-Josée Terrier-Lacombe, (unknown), Philippe Beuzeboc, B. Chauvet, Christine Chevreau, J.C. Eymard, Thierry Lesimple, Yacine Merrouche, Stéphane Oudard, Frank Priou, (unknown), Sophie Gourgou, Stéphane Culine	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact